Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.Ĭarefully consider the risks and benefits of treatment with HUMIRA prior to initiating therapy in patients: 1.Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis.
Initiate treatment for latent TB prior to HUMIRA use. Test patients for latent TB before HUMIRA use and during therapy. Patients with TB have frequently presented with disseminated or extrapulmonary disease.
Active tuberculosis (TB), including reactivation of latent TB.Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.ĭiscontinue HUMIRA if a patient develops a serious infection or sepsis. Patients treated with HUMIRA are at increased risk for developing serious infections that may lead to hospitalization or death. To learn about AbbVie’s privacy practices and your privacy choices, visit IMPORTANT SAFETY INFORMATION for HUMIRA (adalimumab) 1 This assistance offer is not health insurance. Patients who are members of insurance plans that claim to reduce or eliminate their patients’ out of pocket co-pay, co-insurance, or deductible obligations for certain prescription drugs based upon the availability of, or patient’s enrollment in, manufacturer sponsored co-pay assistance for such drugs (often termed “maximizer” programs) will have an annual maximum program benefit of $6,000.00 per calendar year.
Restrictions, including monthly maximums, may apply. Offer subject to change or discontinuance without notice. Patients may not seek reimbursement for value received from the HUMIRA Complete Program from any third-party payers. Patients residing in or receiving treatment in certain states may not be eligible. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government-funded healthcare program, patient will no longer be able to use the HUMIRA Complete Savings card and patient must call HUMIRA Complete at 1-800-4HUMIRA to stop participation. Co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare, Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. Eligibility: Available to patients with commercial prescription insurance coverage for HUMIRA who meet eligibility criteria.
OTEZLA COPAY CARD PLUS
This benefit covers HUMIRA ® (adalimumab) alone or, for rheumatology patients, HUMIRA plus one of the following medications: methotrexate, leflunomide (Arava ®), or hydroxychloroquine (Plaquenil ®). They are trained to direct patients to their HCP for treatment-related advice, including further referrals.
OTEZLA COPAY CARD PROFESSIONAL
*Nurse Ambassadors are provided by AbbVie and do not work under the direction of your health care professional (HCP) or give medical advice. Providing a Sharps Container to dispose of used Pens and syringesįield Access Specialists and Insurance Specialists will continue to provide ongoing assistance with prescription status, access issues (including national/regional payer polices), and reimbursement.
OTEZLA COPAY CARD HOW TO
0 kommentar(er)
